Clinical Trials | March 23, 2023
Osteoarthritis candidate MM-II showed durable pain relief in Global Phase 2b study
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
Various healthcare companies are already implementing high-tech solutions into existing healthcare systems.
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
Agasta Software is engaged in research, development and commercialization of medical devices
The new sterile filling line meets cGMP aseptic filling regulatory requirements
Subscribe To Our Newsletter & Stay Updated
